Vir Biotechnology
213 hedge funds and large institutions have $611M invested in Vir Biotechnology in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 81 reducing their positions, and 26 closing their positions.
95% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $742K
9% more capital invested
Capital invested by funds: $558M → $611M (+$52.6M)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% more funds holding
Funds holding: 213 → 213 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.1% less ownership
Funds ownership: 80.13% → 77.03% (-3.1%)
25% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 81
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$5.4M |
| 2 |
Millennium Management
New York
|
+$4.03M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$2.66M |
| 4 |
Two Sigma Investments
New York
|
+$1.43M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.35M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.6M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$3.99M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.19M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.96M |
VIR Hedge Fund Activity: Q3 2025 in Review
213 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2025, worth a combined $611M — up 9.4% from $558M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VIR positions and 26 closed out — a net gain of 2 holders — while 61 added to existing stakes and 81 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.4M. The largest seller was Citadel Advisors, cutting an estimated $13.6M.
- 213 institutional investors held Vir Biotechnology (VIR) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $611M of Vir Biotechnology stock for Q3 2025, up 9.4% quarter-over-quarter.
- 28 funds opened new Vir Biotechnology positions in Q3 2025 and 26 closed out, a net change of +2 holders.
- The largest Vir Biotechnology buyer in Q3 2025 was Morgan Stanley, an estimated $5.4M added.
- The largest Vir Biotechnology seller in Q3 2025 was Citadel Advisors, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2025.